FPH - Fisher Paykel Healthcare.

[winner69]

Leaving guidance of full year revenues at $1.7 billion implies (at this stage) no growth in second half of year …..even with NZD where it is

Can’t be right

[winner69]

Forbar retail their UNDERPERFORM on FPH

Future earnings look good they say but they ‘believe that a near-best-case long-term earnings scenario is priced by the market.’

No doubt Kingfish would disagree

[bull....]

quite a few big asx healthcare stocks being pummelled after results due to margin squeeze ..... be surprised if fph is not affected similarly

i did a bit more digging on why some of these healthcare stocks getting pummelled resmed ( asx ) in particular its because of the newly approved obesity drugs ( the new wonder drugs apparently ) anyway some say this will effect demand for sleep apnea products

short interest has jumped in both resmed and fph recently too on this drug news.

i will watch with interest if these drugs do in time disrupt the sleep apnea market

[alokdhir]

i did a bit more digging on why some of these healthcare stocks getting pummelled resmed ( asx ) in particular its because of the newly approved obesity drugs ( the new wonder drugs apparently ) anyway some say this will effect demand for sleep apnea products

short interest has jumped in both resmed and fph recently too on this drug news.

i will watch with interest if these drugs do in time disrupt the sleep apnea market

ResMed is mainly 75% Sleep apnea dependent company while FPH is more hospital humidification dependent business ...FPH has world class hospital humidification equipment and thats under no threat from less obese people leading to less sleep apnea ...they sell mainly sleep apnea masks ...their devices are not very customer friendly thus their home care business is also ran type ...

ResMed is on BUY radar of even Morningstar now !!!

[lissica]

i did a bit more digging on why some of these healthcare stocks getting pummelled resmed ( asx ) in particular its because of the newly approved obesity drugs ( the new wonder drugs apparently ) anyway some say this will effect demand for sleep apnea products

short interest has jumped in both resmed and fph recently too on this drug news.

i will watch with interest if these drugs do in time disrupt the sleep apnea market

The GLP-1 agonists work better than anything we've had before, but they're not going to eliminate obesity or sleep apnoea.

[Joshuatree]

ResMed is mainly 75% Sleep apnea dependent company while FPH is more hospital humidification dependent business ...FPH has world class hospital humidification equipment and thats under no threat from less obese people leading to less sleep apnea ...they sell mainly sleep apnea masks ...their devices are not very customer friendly thus their home care business is also ran type ...

ResMed is on BUY radar of even Morningstar now !!!

Both stocks are re 36% down off their highs.They are looking attractive value imo. Quite a few unpleasant side effects with the obesity drugs and many folks without obesity have sleep apnoea. Not forgetting smoking (perish the thought is an appetite suppressor. Im assuming vaping is too let alone the good old fave appetite suppressor (for me anyways) coffee! Also both companies being reasonably mature just have to spend a little less on huge research budgets to increase their margins.

[winner69]

Both RMD and FPH share prices apparently been impacted by these obesity drug hype ….pretty strong correlation last few months

Interesting there’s a strong correlation between RMD and an outfit CCX on ASX (Citychic)

Obesity drug hype = No more fat people = no revenue for Citychic (who specialise in big size clothes)

Hope just a hype

[winner69]

Share price fallen to where Forbar can raise its rating to neutral ..that’s cool

From businessdesk

Forsyth Barr analysts have upgraded their rating of Fisher & Paykel Healthcare to neutral following recent share-price weakness.

They said the weakening NZD/USD and Fisher & Paykel's defensive qualities in an uncertain market is the reason for the rating lift.

"In the absence of material earnings downgrades, we struggle to see catalysts to drive the share price materially lower."

Forsyth Barr analysts Matt Montgomerie and Benjamin Crozier said Fisher & Paykel's earnings multiple had puzzled them for some time, but with the market pricing long-term revenue growth of 9% and Ebit (earnings before interest and taxes) margins of 28%, they forecast strong near-term earnings growth.

They said they came away with three takeaways from Fisher & Paykel's recent investor day: the long-term growth runway remains strong, and Fisher & Paykel continues to be well positioned, the gross margin recovery back to the company's 65% target will take time, and covid-19 is no silver bullet.

[kiora]

FPH From a glass preserving jar bubbling water through it to listing in 2001 & T/O $1.5 b in 2023
https://en.wikipedia.org/wiki/Fisher...thcare#History
I bought a far chunk at IPO $4.doubled down at $3.00 when SP dropped over ensuring months
Why?

At IPO I was impressed by GR,R&D % of T/O,GP margins, return on R&D, low debt level, self funding its own growth, management INC etc

No other company in NZ spends more % T/O than FPH & hold more patents on their research that I know of.
https://www.fphcare.com/nz/corporate/about-us/patents/
These are not easy to obtain
It churns out cash.
It has never had to hold out its hand to shareholders for more
It has self funded its growth
R&D & manufacturing facilities have never had to change except to keep up with its growth
It has insignificant debt
Insignificant market announcements regarding detrimental issues of the company
Management looks after interests of all stake holders
( As does IFT management)

I have accumulated more through DRIP(no capital raises since IPO?) & even though sold 10% ? few years ago still got more than I brought in first year

I can see no reason to change this view gained at IPO

[winner69]

FPH share price often follows RMD and this new drug seems to be affecting both

Had to smile with these on X -

@berthon_jones
$RMD resumes falling into the sea as GLP-1s continuing to demonstrate “good for what ails you”. We’d thought ourselves clever buying below $25, but it is quite relentless out there, as the register churns over.

And one of his followers replied

Lly trials results for osa due Mar 24 more bad news coming in next 6 months imo.

They reckon RMD share price heading to $15

Heck if FPH follows suit we could see it’s share price well below $20

Hope not as that’ll stuff KFL up …and golly gosh Burrimundi as well as they love RMD